Endocrine Abstracts

Introduction: In Mexico there is scant literature about medical management and its response in patients with acromegaly. Octreotide LAR at a dosage of 20 mg weekly is considered as first line treatment in patients who failed to surgery or who are not candidates to surgical treatment. The goal of this initial dosage is to reach GH levels below 1.0 ng/ml and insuline like factor type 1 (IGF1) levels within range for age and gender. The objective of this study is to determine the...

Background: Acromegaly results from excess growth hormone (GH) secretion by a pituitary adenoma in 95% of the cases. Discordant acromegaly is defined by the elevation of GH with normal levels of insulin-like growth factor type 1 (IGF-1) or normal levels of GH associated with an elevation of IGF-1. Its an important situation in the follow-up period of patients with acromegaly because there is little information about patient treatment, comorbidities and follow-up. The objective...